Our Pricing

Is Wegovy Safe for Weight Loss? Switch & Save Guide

If you're asking is Wegovy safe for weight loss UK, you're making the right choice by researching first. As a UK-registered pharmacy with thousands of weight loss patients under our care, we've seen Wegovy transform lives when prescribed appropriately — but like all prescription medications, it requires proper clinical assessment and monitoring by UK prescribers.

Wegovy Safety Profile: What Clinical Trials Show

Wegovy (semaglutide 2.4mg) has been extensively studied across the STEP clinical trial programme, involving over 4,500 participants worldwide [1]. In the pivotal STEP 1 trial, participants achieved an average 14.9% body weight reduction over 68 weeks, with the medication demonstrating a consistent safety profile throughout the study period [1].

The MHRA licensed Wegovy in the UK in 2023 after rigorous evaluation of this safety data. Most adverse events reported were gastrointestinal in nature — nausea, diarrhoea, and constipation — and were typically mild to moderate, occurring primarily during dose escalation [1]. Importantly, discontinuation rates due to side effects remained below 7% across the STEP trials, indicating most patients tolerate the medication well when titrated appropriately [2].

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that proper dose escalation is critical to minimising side effects. The Wegovy regimen starts at 0.25mg weekly and gradually increases over 16-20 weeks, allowing your body to adapt to the medication's effects on gastric emptying and appetite regulation.

Who Should Not Take Wegovy: Contraindications and Precautions

Wegovy is not suitable for everyone, which is why all prescriptions at Cured Pharmacy require clinical assessment by a UK-registered prescriber. Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and hypersensitivity to semaglutide or any excipients [3].

Your prescriber will also carefully evaluate your medical history for conditions requiring additional monitoring. These include previous pancreatitis, severe gastrointestinal disease, diabetic retinopathy (particularly in type 2 diabetes patients), and renal impairment [3]. Pregnant or breastfeeding women should not use Wegovy, and the medication should be discontinued at least 2 months before planned conception.

During your free online consultation — which takes under 3 minutes — our UK clinical team will review your complete medical history, current medications, and weight loss goals to determine if Wegovy is the safest and most appropriate option for you.

Drug Interactions to Consider

Semaglutide can delay gastric emptying, potentially affecting the absorption of oral medications. If you take medications with narrow therapeutic windows — such as warfarin, levothyroxine, or certain diabetes medications — your prescriber may recommend additional monitoring or timing adjustments [3]. Always disclose all current medications, including over-the-counter products and supplements, during your consultation.

Common Side Effects: What to Expect When Starting Wegovy

The most frequently reported side effects in clinical trials were gastrointestinal: nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects typically emerge during dose escalation and diminish as your body adapts to the medication.

In our experience dispensing Wegovy to thousands of UK patients, we've found that simple strategies significantly improve tolerance. Taking the injection on the same day each week, staying well-hydrated, eating smaller meals, and avoiding high-fat foods can reduce gastrointestinal discomfort. Most patients report that nausea peaks within 24-48 hours post-injection and resolves before the next dose.

Less common but important side effects include injection site reactions (typically mild redness or itching), fatigue, and dizziness. Serious adverse events are rare but include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients also taking other glucose-lowering medications) [2][3]. If you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction, seek immediate medical attention.

Managing Side Effects Effectively

Your prescriber may recommend temporarily pausing dose escalation if side effects become troublesome, allowing your body additional time to adjust. This individualised approach — supported by our UK clinical team throughout your treatment — helps maximise both safety and treatment adherence.

Is Wegovy Safe for Weight Loss UK: Long-Term Safety Data

Beyond the initial 68-week STEP trials, extension studies have evaluated semaglutide safety for up to 2 years of continuous use [4]. These longer-term studies confirmed that the safety profile remains consistent with no new safety signals emerging with extended treatment duration.

Cardiovascular safety is a critical consideration for any weight loss medication. The SELECT trial, published in 2023, demonstrated that semaglutide 2.4mg significantly reduced major adverse cardiovascular events in adults with established cardiovascular disease — a 20% reduction compared to placebo [5]. This landmark finding suggests Wegovy may offer cardiovascular protection beyond weight loss alone, though the trial studied a specific high-risk population.

Regular monitoring by your prescriber is essential for long-term safety. At Cured Pharmacy, patients on Wegovy receive ongoing clinical support, with prescribers reviewing progress, side effects, and any changes in health status at each prescription renewal. This continuity of care ensures any emerging concerns are identified and addressed promptly.

Switching to Wegovy from Other Weight Loss Treatments

Many patients ask about switching from other weight loss medications to Wegovy. If you're currently taking an alternative GLP-1 receptor agonist such as Saxenda (liraglutide), your prescriber will typically recommend stopping the previous medication before starting Wegovy, as combining GLP-1 treatments is not advised [3].

Switching from oral treatments like Orlistat or Mysimba is more straightforward, as these work through different mechanisms. However, your prescriber will still conduct a full clinical assessment to ensure Wegovy is appropriate given your current health status and treatment response.

The transition process at Cured Pharmacy is seamless. During your online consultation, simply indicate your current weight loss treatment, and our UK prescribers will provide personalised guidance on timing, dose initiation, and what to expect during the switch. Transparent upfront pricing means you'll see the cost — from £79.00 — before completing your consultation.

Why Patients Switch to Wegovy

Common reasons for switching include inadequate weight loss with current treatment, tolerability issues with daily injections (Saxenda requires daily administration versus Wegovy's once-weekly dosing), or preference for a medication with robust cardiovascular safety data. Your prescriber will help determine whether switching aligns with your treatment goals.

How to Access Wegovy Safely Through Cured Pharmacy

Wegovy is a prescription-only medication in the UK, meaning it can only be supplied following clinical assessment by a UK-registered prescriber. At Cured Pharmacy (GPhC Registration Number 9012511), we've designed a process that prioritises both safety and convenience.

Your journey begins with a free online consultation taking under 3 minutes. You'll answer questions about your medical history, current medications, weight loss goals, and any previous weight management treatments. A UK-registered prescriber reviews your responses and, if clinically appropriate, issues a prescription that our pharmacy team dispenses using only genuine UK-licensed Wegovy pens.

We guarantee 100% discreet packaging and competitive pricing in the UK. Unlike some providers who hide costs until after consultation, our transparent approach shows you the price from £79.00 upfront, so you can make an informed decision before starting your assessment. All medications are dispensed from our UK pharmacy and delivered directly to your door with tracked shipping.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2473–2481. https://doi.org/10.1038/s41591-023-02502-2
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on adherence to treatment and lifestyle modifications.